Conditioning therapy with N‐acetyl‐L‐cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26903
Abstract: Conditioning therapy is an essential procedure prior to hematopoietic stem cell transplant (HSCT), imposing a great impact on the outcomes of recipients. We performed a prospective randomized controlled trial to assess the outcome of HSCT… read more here.
Keywords: arm; decitabine; myeloid malignancies; therapy ... See more keywords
Decitabine inhibits tumor cell proliferation and up‐regulates e‐cadherin expression in Epstein–Barr virus‐associated gastric cancer
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Virology"
DOI: 10.1002/jmv.24634
Abstract: The present study investigated the effect of a DNA demethylating agent, decitabine, against Epstein–Barr virus‐associated gastric cancer (EBVaGC). Decitabine inhibited cell growth and induced G2/M arrest and apoptosis in EBVaGC cell lines. The expression of… read more here.
Keywords: epstein barr; decitabine; barr virus; virus associated ... See more keywords
Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Hematology"
DOI: 10.1007/s00277-017-3185-5
Abstract: In contrast to the evidence regarding azacitidine (Aza), there is limited knowledge about the combination of decitabine (DAC) and donor lymphocyte infusions as salvage therapy for relapse after allogeneic stem cell transplantation (allo-SCT) so far.… read more here.
Keywords: aml mds; dac; cell transplantation; decitabine ... See more keywords
Efficacy of decitabine as hemoglobin F inducer in HbE/β-thalassemia
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3357-y
Abstract: To study safety, efficacy (hemoglobin and hemoglobin F percentage increment in non-transfusion-dependent patients and decrease in transfusion frequency in transfusion-dependent patients), and determinants of response of decitabine in patients with HbE/β-thalassemia. Thirty patients of HbE/β-thalassemia… read more here.
Keywords: decitabine; transfusion dependent; hbe thalassemia; hemoglobin ... See more keywords
Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer
Sign Up to like & getrecommendations! Published in 2019 at "Investigational New Drugs"
DOI: 10.1007/s10637-019-00854-9
Abstract: Purpose The objective of this mass balance trial was to determine the excretory pathways and metabolic profile of the novel anticancer agent guadecitabine in humans after administration of a 14C-radiolabeled dose of guadecitabine. Experimental design… read more here.
Keywords: mass balance; guadecitabine; 14c guadecitabine; mass ... See more keywords
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01948-8
Abstract: Decitabine (5-aza-2′-deoxycytidine) is a hypomethylating agent used in the treatment of acute myeloid leukemia (AML). Decitabine inhibits DNA methyltransferases, causing DNA hypomethylation, and limiting the transcription of tumor suppressor genes, leading to gene silencing. Decitabine… read more here.
Keywords: myeloid leukemia; treatment; monotherapy patients; decitabine ... See more keywords
Therapeutic effect of TRC105 and decitabine combination in AML xenografts
Sign Up to like & getrecommendations! Published in 2020 at "Heliyon"
DOI: 10.1016/j.heliyon.2020.e05242
Abstract: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, often characterized by poor prognosis following standard induction therapy. The hypomethylating agent decitabine (DAC) is an alternative treatment for elderly and relapsed/refractory AML patients, yet responses… read more here.
Keywords: combination; dac; decitabine; aml xenografts ... See more keywords
Decitabine attenuates nociceptive behavior in a murine model of bone cancer pain
Sign Up to like & getrecommendations! Published in 2019 at "PAIN"
DOI: 10.1097/j.pain.0000000000001442
Abstract: Abstract Bone cancer metastasis is extremely painful and decreases the quality of life of the affected patients. Available pharmacological treatments are not able to sufficiently ameliorate the pain, and as patients with cancer are living… read more here.
Keywords: bone cancer; cancer pain; decitabine; cancer ... See more keywords
Efficacy of decitabine combined with allogeneic hematopoietic stem cell transplantation in the treatment of recurrent and refractory acute myeloid leukemia (AML): A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000030644
Abstract: Background: This analysis aimed to assess the effect of decitabine combined with allogeneic hematopoietic stem cell transplantation (allo-HSCT) in treating recurrent and refractory acute myeloid leukemia. Method: The present analysis was carried out according to… read more here.
Keywords: acute; decitabine; leukemia; transplantation ... See more keywords
Abstract A169: Combination of TPC-144, a reversible LSD1 inhibitor, and a hypomethylating agent resulted in synergistic antitumor efficacy in preclinical models of AML
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-a169
Abstract: Background: Lysine-specific demethylase 1A (LSD1/KDM1A) is a flavin adenine dinucleotide (FAD)-dependent histone demethylase that specifically modifies histone H3 lysine 4 and lysine 9. LSD1 activity is implicated in the pathogenesis of several human cancers, and… read more here.
Keywords: combination; inhibitor; efficacy; decitabine ... See more keywords
DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Investigation"
DOI: 10.1172/jci97924
Abstract: Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis that lacks targeted therapies, especially in patients with chemotherapy-resistant disease. Since DNA methylation-induced silencing of tumor suppressors is common in cancer, reversal of promoter… read more here.
Keywords: negative breast; dna; breast cancer; decitabine ... See more keywords